Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
| Publication | |
| Title | |
| Authors |
|
| Journal | NEJM |
| Date | July 23, 2020 |
A randomized, open-label controlled trial of 504 patients with mild-to-moderate COVID-19 were treated with standard care, hydroxychloroquine or hydroxychloroquine plus azithromycin resulted in no difference in clinical status at 15 days.
Although described by critics of hydroxychloroquine to qualify as an "early treatment" trial, of note, the median time between symptoms onset and randomization was reported to be 7 days and included patients up to 14 days after symptom onset. Notably this is a greater delay in treatment compared to other early treatment studies such as the one by Dr. Vladimir Zelenko (COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxychloroquine and Azithromycin: A Retrospective Case Series Study) which had a median time between symptom onset and treatment of only 4 days.
Major Issues
Contribute here!
Minor Issues
Contribute here!
Impact
Contribute here!
Article Revisions
No revisions reported at this time.